HANAVAX

hanavax-logo

HanaVax is a drug discovery venture that develops next-generation nasal vaccines.In addition to systemic immunity, nasal vaccines that can induce mucosal immunity to the respiratory mucosa, which is the entry point for pathogens, are considered the most effective vaccines for respiratory infections. Nanogel is a cholesterol pullulan that has already been confirmed to be safe in humans, and can induce mucosal immunity more effectively by cationization. Induction of both systemic and mucosal immun... ity by effectively delivering vaccine and adjuvant to immunocompetent cells by encapsulating the vaccine antigen alone or in a nanogel with an adjuvant and introducing it into the mucosa via nasal administration It is a system that can do it. Vaccine adjuvant encapsulated in cationized nanogels is easily taken up by epithelial cells. The cationized nanogel acts as an artificial molecular chaperone to maintain the structure of the vaccine, efficiently delivering vaccine antigens to dendritic cells below the basement membrane of epithelial cells, effectively presenting the antigens to the immune system, and generating a strong immune response. Induces both mucosal and systemic systems. In other words, the cationized nanogel nasal delivery system elicits the two-stage protective immunity of humans and prevents the development of infectious diseases.

#People #Financial #Website #More

HANAVAX

Industry:
Health Care Hospital Medical Device

Founded:
2016-12-27

Address:
Tokyo, Tokyo, Japan

Country:
Japan

Website Url:
http://www.hanavax.co.jp

Status:
Active

Total Funding:
0

Technology used in webpage:
Domain Not Resolving Google Google Cloud Wix Hosted Google Cloud Taiwan


Current Employees Featured

not_available_image

Ki Rakaraboshi
Ki Rakaraboshi President & CEO @ HanaVax
President & CEO
2017-01-01

Investors List

fast-track-initiative_image

Fast Track Initiative, Inc.

Fast Track Initiative, Inc. investment in Seed Round - HanaVax

fast-track-initiative_image

Fast Track Initiative, Inc.

Fast Track Initiative, Inc. investment in Seed Round - HanaVax

Official Site Inspections

http://www.hanavax.co.jp Semrush global rank: 5.24 M Semrush visits lastest month: 1.56 K

  • Host name: unalocated.63.wixsite.com
  • IP address: 185.230.63.171
  • Location: Ashburn United States
  • Latitude: 39.018
  • Longitude: -77.539
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 20147

Loading ...

More informations about "HanaVax"

HanaVax - Crunchbase Company Profile & Funding

HanaVax is a drug discovery venture that develops next-generation nasal vaccines.In addition to systemic immunity, nasal vaccines that can induce mucosal immunity to the respiratory …See details»

塩野義製薬とHanaVax社とのカチオン化ナノ

Jul 19, 2021 塩野義製薬とHanaVax社は、アンメットメディカルニーズを満たす画期的な次世代経鼻ワクチンの提供を通じて、COVID-19の脅威から人々を解放するため、感染症領域における塩野義製薬の強みと、粘膜免疫学のパイオ …See details»

HanaVax Company Profile 2024: Valuation, Funding & Investors

HanaVax General Information Description. Developer of nasal vaccines designed for bacterial and viral infections. The company's vaccines retain antigens on respiratory mucosal surfaces for a …See details»

HANAVAX INC. Company Profile | CHUO-KU, TOKYO, Japan

Find company research, competitor information, contact details & financial data for HANAVAX INC. of CHUO-KU, TOKYO. Get the latest business insights from Dun & Bradstreet.See details»

Press Release - Shionogi

Upfront payment to HanaVax in for exclusive worldwide rightsreturn to this vaccine candidate. HanaVax will be eligible to receive additional development milestones and royalties based on …See details»

株式会社HanaVaxの会社情報と資金調達 | NIKKEI COMPASS - 日本 …

【NIKKEI COMPASS】株式会社HanaVaxは、「次世代型経鼻ワクチン」の開発を行う創薬ベンチャー企業。 サービスとして、既存の注射型ワクチンと異なり ...See details»

HanaVax Company Profile - Office Locations, Competitors ... - Craft

HanaVax is a company devoted to the development of nasal vaccines against infectious diseases. Its products are designed to stimulate protective mucosal as well as systemic immunity. The …See details»

塩野義製薬とHanaVax、経鼻肺炎球菌ワクチンに関するライセン …

【プレスリリース】発表日:2020年9月30日塩野義製薬とHanaVax社との経鼻肺炎球菌ワクチンに関するライセンス契約の締結について塩野義製薬 ...See details»

塩野義製薬、塩野義製薬とHanaVax社との経鼻肺炎球菌ワクチン …

Oct 1, 2020 塩野義製薬株式会社(本社:大阪市中央区、代表取締役社長:手代木 功、以下「塩野義製薬」)と東京大学発の創薬ベンチャーである株式会社HanaVax(本社:東京都中央区 …See details»

塩野義、経鼻ワクチン技術のHanaVaxと新たな契約:日経バイオ …

塩野義製薬は2021年7月19日、東京大学医科学研究所の清野宏特任教授が創業者で取締役を務めるHanaVax(東京・中央、石丸瑞洋社長)と、カチオン化ナノゲルデリバリーシステ …See details»

塩野義製薬とHanaVax社との経鼻肺炎球菌ワクチンに関する

Sep 30, 2020 株式会社HanaVaxについて HanaVaxは、「経鼻ワクチンで健康社会を創出する」をミッションに、粘膜免疫学研究とナノゲル研究の草分け的存在の東京大学および千葉大学 …See details»

Shionogi and HanaVax Enter into a License Agreement for …

Sep 30, 2020 Osaka and Tokyo, Japan, September, 30, 2020 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and …See details»

Non-Injectable Mucosal Vaccines Providing Safe and Less Stressful ...

Jul 26, 2022 At present, the effectiveness has been confirmed in different species ranging from mice to monkeys. The cationized nanogel nasal vaccine for S. pneumoniae has been licensed …See details»

COVID nasal spray vaccine set to enter clinical trial in Japan

Sep 29, 2021 OSAKA -- Shionogi will start clinical trials for a COVID-19 nasal spray vaccine in fiscal 2022, the Japanese pharmaceutical company announced Tuesday, paving the way for …See details»

塩野義製薬とHanaVax社とのカチオン化ナノゲルデリバリーシス …

Jul 20, 2021 塩野義製薬株式会社(本社:大阪市中央区、代表取締役社長:手代木 功、以下「塩野義製薬」または「当社」)と東京大学発の創薬ベンチャーである株式会社HanaVax(本 …See details»

HanaVax - Products, Competitors, Financials, Employees, …

Headquarters Location. MG Meguro Ekimae, 722 2-15-19 Kamiosaki, Shinagawa-ku. Tokyo, 141-0021, Japan. 81 3 4540 1752See details»

Shionogi and HanaVax Enter into a License Agreement for COVID …

Jul 19, 2021 Osaka and Tokyo, Japan, July, 19, 2021 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and HanaVax …See details»

Tuberculosis vaccine - HanaVax - AdisInsight - Springer

Tuberculosis vaccine - HanaVax Latest Information Update: 02 Oct 2021. Price : $50 * Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. Final gross …See details»

HanaVax - Company Profile - Tracxn

Oct 21, 2024 HanaVax ranks 213th among 303 active competitors. 87 of its competitors are funded while 59 have exited. Overall, HanaVax and its competitors have raised over $7.51B in …See details»

Shionogi and HanaVax Enter into a License Agreement for COVID …

Shionogi and HanaVax Enter into a License Agreement for COVID-19 Vaccine Development Using Cationic Nanogel Delivery SystemSee details»

linkstock.net © 2022. All rights reserved